Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats
暂无分享,去创建一个
E. Kamiyama | A. Kurihara | Y. Miyaji | O. Okazaki | K. Kawai | T. Shiiki
[1] Paolo Vicini,et al. Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[2] Frédéric Blanchard,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK , 2006 .
[3] S. Ricard-Blum,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. , 2006, Biochemical and biophysical research communications.
[4] J. Patsch,et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. , 2005, The Journal of clinical endocrinology and metabolism.
[5] S. Jurisson,et al. Radioiodination of Rhenium Cyclized α-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma , 2004, Cancer Research.
[6] Steven W. Martin,et al. Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] Steven W. Martin,et al. A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.
[8] T. Plesner,et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. , 2002, Blood.
[9] S. Mochizuki,et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats , 2002, Journal of Bone and Mineral Metabolism.
[10] P. Kostenuik,et al. OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats , 2001 .
[11] C. Davis,et al. Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. , 2001, The Journal of pharmacology and experimental therapeutics.
[12] A. Nakanishi,et al. The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[14] P. Kostenuik,et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. , 2000, Cancer research.
[15] S. Morony,et al. A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .
[16] K. Ikeda,et al. Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Morony,et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] Y. Courtois,et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. , 1999, Molecular pharmacology.
[20] S. Mochizuki,et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. , 1998, Biochemical and biophysical research communications.
[21] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[22] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[24] M. Goto,et al. Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.
[25] Y. Kato,et al. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[26] S. Mochizuki,et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.
[27] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[28] R. Mahley,et al. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. , 1995, Journal of lipid research.
[29] P. Godowski,et al. The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. , 1994, Endocrinology.
[30] M. Hashida,et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. , 1989, Journal of pharmaceutical sciences.
[31] M. Hashida,et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I: Synthesis and characterization. , 1989, Journal of pharmaceutical sciences.